Merck’s Keytruda swung and missed in endometrial cancer for the second time in six months. Thursday, the pharma giant announced that its bestseller flopped in a Phase III trial in high-risk disease.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,